{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sun Pharma Advanced Research Company Ltd
Why is SPARC falling/rising?
As of 16-Dec, Sun Pharma Advanced Research Company Ltd (SPARC) shares have continued their downward trajectory, closing at ₹132.80 with a decline of 2.57% on the day. The stock’s persistent underperformance reflects a combination of deteriorating financial metrics and subdued investor sentiment.
Sun Pharma Advanced Research Company Hits Intraday Low Amid Price Pressure
Sun Pharma Advanced Research Company experienced a notable decline today, touching an intraday low of Rs 140.4, reflecting a price pressure of 8.15% during the session. This underperformance contrasted with broader market movements and sector trends, signalling immediate pressures on the stock.
Sun Pharma Advanced Research Company Hits Intraday High with Strong Trading Momentum
Sun Pharma Advanced Research Company recorded a robust intraday performance today, reaching a high of Rs 174.25, reflecting an 8.16% rise during the trading session. The stock outpaced its sector and broader market indices, demonstrating notable volatility and sustained upward momentum.
Sun Pharma Advanced Research Company Surges with Unprecedented Buying Interest
Sun Pharma Advanced Research Company Ltd has witnessed extraordinary buying momentum, with the stock hitting an upper circuit and only buy orders in the queue, signalling a potential multi-day rally amid strong investor enthusiasm.
Sun Pharma Advanced Research Company Hits Intraday High with Strong Trading Momentum
Sun Pharma Advanced Research Company recorded a robust intraday performance today, reaching a high of Rs 145.95, reflecting an 8.72% rise amid heightened volatility and notable trading activity.
SPARC’s Evaluation Revised Amidst Challenging Financial and Market Conditions
SPARC, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing financial and operational challenges. This shift highlights the company’s current standing amid a difficult market environment and persistent underperformance relative to its peers and benchmarks.
Sun Pharma Advanced Research Company Shows Mixed Technical Signals Amid Price Momentum Shift
Sun Pharma Advanced Research Company (SPARC) has experienced a notable shift in its technical parameters, reflecting a nuanced change in price momentum. Recent data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, with key technical indicators such as MACD, RSI, and moving averages presenting a complex picture for investors analysing the pharmaceutical and biotechnology sector.
Sun Pharma Advanced Research Company Faces Technical Momentum Shift Amid Market Challenges
Sun Pharma Advanced Research Company (SPARC) is currently exhibiting a notable shift in its technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent evaluation adjustments highlight a transition in key technical indicators, signalling a more cautious outlook for investors amid broader market pressures.
Sun Pharma Advanced Research Company Sees Shift in Technical Momentum Amid Market Volatility
Sun Pharma Advanced Research Company (SPARC) has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and investor sentiment within the Pharmaceuticals & Biotechnology sector. Recent price movements and technical indicators suggest a nuanced transition in the stock’s trend, warranting close attention from market participants.
Why is SPARC falling/rising?
As of 18-Nov, Sun Pharma Advanced Research Company Ltd's stock is at 129.35, down 1.71%, and has underperformed its sector. The company faces significant financial challenges, including declining sales and profits, resulting in a year-to-date decline of 35.41%.
Sun Pharma Advanced Research Faces Significant Financial Challenges Amidst Market Underperformance
Sun Pharma Advanced Research Company (SPARC) has reported a net profit after tax of Rs -127.72 crore over the past six months, reflecting a 41.02% decline. With low net sales of Rs 7.86 crore and high interest expenses, the company faces significant financial challenges in the competitive pharmaceuticals sector.
How has been the historical performance of SPARC?
SPARC has faced significant financial challenges over the past three years, with net sales declining from 238.78 Cr in March 2023 to 71.77 Cr in March 2025, and increasing losses reflected in negative operating profit and profit after tax. Despite some cost control efforts, the company has seen a substantial decrease in total assets and liabilities, alongside persistent negative cash flow from operating activities.
How has been the historical performance of SPARC?
SPARC has experienced a significant decline in financial performance over the past three years, with net sales dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025, and operating losses worsening from -203.18 crore to -321.35 crore in the same period. Overall, the company's financial metrics indicate ongoing operational challenges.
Are SPARC latest results good or bad?
SPARC's latest results are concerning, showing a net loss of ₹75.85 crores and a 38.88% decline in revenue year-over-year, alongside a negative operating margin of -836.13%. The company's financial position is critical, with negative book value and rising debt, indicating significant operational challenges and no clear path to profitability.
SPARC Q2 FY26: Mounting Losses Deepen as Revenue Collapses 39% YoY
Sun Pharma Advanced Research Company Ltd. (SPARC) reported a dismal second quarter for FY2026, with net losses widening to ₹75.85 crores—a 29.33% deterioration from the year-ago period—as the clinical-stage biopharmaceutical company continues to struggle with collapsing revenues and mounting operational inefficiencies. With a market capitalisation of ₹4,190 crores, the small-cap pharmaceutical research firm faces an increasingly precarious financial position as revenue plunged 38.88% year-on-year to just ₹7.86 crores in Q2 FY26, marking the lowest quarterly sales figure in recent history.
Is SPARC technically bullish or bearish?
As of November 4, 2025, SPARC is in a bearish trend with moderate strength, supported by bearish moving averages and indicators like KST and Bollinger Bands, despite a mildly bullish weekly MACD signal.
Sun Pharma Advanced Research Faces Technical Trend Shifts Amid Market Challenges
Sun Pharma Advanced Research Company (SPARC) has experienced a recent stock price decline, reflecting ongoing challenges in the market. Technical indicators show mixed signals, with a bearish sentiment prevailing. Comparatively, SPARC's performance has lagged significantly behind the Sensex, with notable declines over both the year and the past three years.
Is SPARC technically bullish or bearish?
As of November 4, 2025, the market trend has shifted to a bearish stance with moderate strength, driven by bearish signals from daily moving averages, KST, and Bollinger Bands, despite a mildly bullish MACD on the weekly chart.
Is SPARC technically bullish or bearish?
As of November 3, 2025, SPARC's technical trend is mildly bearish, influenced by a bearish monthly MACD and KST, despite a mildly bullish weekly MACD, with mixed signals across various indicators.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
